Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves First Treatment for Rare Skin Cancer

FDA news release; 2017 Mar 23

The FDA has granted accelerated approval to Bavencio (avelumab) for the treatment of metastatic Merkel cell carcinoma (MCC).

Indications: Bavencio is a programmed death ligand-1 blocking antibody indicated for the treatment of adults and pediatric patients 12 years and older with metastatic MCC.

Dosage and administration: Administer 10 mg/kg as an intravenous infusion over 60 minutes every 2 weeks.

Efficacy and safety: Approval is based on data from a single-arm trial of 88 patients with metastatic MCC who received Bavencio. One-third experienced complete or partial shrinkage of their tumors. The response lasted for more than 6 months in 86% percent of responding patients, and more than a year in 45%.

Side effects/risks: The most common adverse reactions are fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, rash, decreased appetite, and peripheral edema.

Citation:

FDA approves first treatment for rare form of skin cancer. [news release]. Silver Spring, MD: FDA March 23, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm548278.htm.... Accessed March 31, 2017.

Bavencio [package insert]. Rockland, MA: EMD Serono, Inc. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf. Accessed March 31, 2017.

This Week's Must Reads

ASCO Guideline on Alcohol Consumption and Cancer, J Clin Oncol; 2018 Jan; LoConte, Brewster, et al

Cochrane On Bisphosphonates for Prostate Cancer, Cochrane; 2017 Dec 26; Macherey, Monsef, et al

Cochrane on Vaccine-Based Immunotherapy for NSCLC, Cochrane; 2017 Dec 16; Zhu, Li, Tiselius, et al

Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22

Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20

Must Reads in FDA Actions

Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22

Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20

Varubi Approved for Delayed Nausea and Vomiting, Tesaro news release; 2017 Oct 25

FDA Approves Keytruda for Advanced Gastric Ca, Merck news release; 2017 Sep 22

FDA Approves Opdivo for Hepatocellular Carcinoma, Bristol-Myers Squibb news release; 2017 Sep 22